Immunology Managed Service Contract

  • NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

F14: Notice for changes or additional information

Notice identifier: 2022/S 000-023220

Procurement identifier (OCID): ocds-h6vhtk-036151

Published 22 August 2022, 10:16am



Section one: Contracting authority/entity

one.1) Name and addresses

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Alder House

St Asaph

LL17 0JL

Contact

Mathew Williams

Email

mathew.williams4@wales.nhs.uk

Telephone

+44 1745366804

Country

United Kingdom

NUTS code

UKL12 - Gwynedd

Internet address(es)

Main address

http://nwssp.nhs.wales/ourservices/procurement-services/

Buyer's address

https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Immunology Managed Service Contract

Reference number

BCU-OJEU-48997

two.1.2) Main CPV code

  • 85111800 - Pathology services

two.1.3) Type of contract

Services

two.1.4) Short description

BCUHB is seeking to appoint a suitably qualified provider to deliver bespoke In Vitro Diagnostics support in delivering Immunology services on the Ysbyty Gwynedd site. This will include equipment, maintenance, consumables, reagents, information technology and training by way of managed service contract


Section six. Complementary information

six.6) Original notice reference

Notice number: 2022/S 022-123180


Section seven. Changes

seven.1) Information to be changed or added

seven.1.2) Text to be corrected in the original notice

Section number

IV.2.2

Place of text to be modified

Time limit

Instead of
Date

30 September 2022

Local time

12:00pm

Read
Date

14 October 2022

Local time

12:00pm

Section number

IV.2.7

Place of text to be modified

Conditions for opening of tenders

Instead of
Date

30 September 2022

Local time

12:00pm

Read
Date

14 October 2022

Local time

12:00pm

seven.2) Other additional information

It has been raised that one of the essential assay, Tryptase, is only available from one provider. Therefore, in order to ensure full transparency and fairness, the specification has now been amended to make Tryptase an Desirable Assay. This will not be included within the commercial scoring, however the Health Board would encourage bidders to provide a solution for this assay in the desirable section of their submission.

In light of this change to the specification, an additional two weeks has been added to the tender period and the new closing date is Friday 14th October 2022 at midday.